In one study TCR β chain complementarity-determining regions in non–small cell lung cancer (NSCLC) treated with checkpoint inhibitors can help determine the degree of overlap of the TCR repertoire between tumor-infiltrating lymphocytes and circulating PD-1+CD8+T cells to determine the shared TCR clones. This evidence concerns the gene CD8A and neoplasm.